Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Daptomycin
Drug ID BADD_D00581
Description Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant _Staphylococcus aureus_ (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid.[A231374, L32534] Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey.[A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.[A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Indications and Usage For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms.
Marketing Status Prescription; Discontinued
ATC Code J01XX09
DrugBank ID DB00080
KEGG ID D01080
MeSH ID D017576
PubChem ID 16134395
TTD Drug ID D05HPI
NDC Product Code 71288-016; 0143-9378; 0703-0125; 0409-5933; 42513-0015; 16729-434; 67254-515; 73402-111; 31722-102; 0409-0122; 43598-413; 63323-585; 71288-017; 71839-107; 68225-082; 43598-476; 42513-0004; 72572-100; 69097-850; 0409-2757; 60977-145; 68225-052; 25021-174; 67919-012; 57885-0011; 25021-179; 72572-102; 69097-807; 70594-034; 51187-0002; 0409-0120; 67184-0549; 16714-892; 17337-0261; 60505-6229; 67457-813; 63323-871; 0781-3295; 71288-018; 16729-435; 63323-371; 68001-467; 68001-376; 55150-344; 70594-053; 71839-108; 67919-011
Synonyms Daptomycin | Deptomycin | Cubicin | Daptomycin, 9-L beta-Aspartic Acid | Daptomycin, 9 L beta Aspartic Acid | LY-146032 | LY 146032 | LY146032
Chemical Information
Molecular Formula C72H101N17O26
CAS Registry Number 103060-53-3
SMILES CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC (=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)C C(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash vesicular23.03.13.009--Not Available
Renal failure20.01.03.0050.000639%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.000213%Not Available
Respiratory disorder22.02.07.0020.000213%Not Available
Respiratory distress22.02.01.0120.001171%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000639%
Rhabdomyolysis15.05.05.0020.008836%
Seizure17.12.03.001--
Sepsis11.01.11.0030.000833%
Septic shock24.06.02.011; 11.01.11.0040.000472%Not Available
Shock24.06.02.002--Not Available
Sinus tachycardia02.03.03.0100.000213%
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin infection23.09.04.002; 11.01.12.0030.000213%
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome12.03.01.014; 23.03.01.007; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.005--
Supraventricular tachycardia02.03.03.0120.000319%
Swelling08.01.03.015--Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Systemic candida11.03.03.0160.000056%Not Available
Tachycardia02.03.02.0070.001171%Not Available
Tachypnoea22.02.01.0140.000319%Not Available
Throat tightness22.02.05.015; 19.01.02.0050.000426%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytosis01.08.02.0010.000213%Not Available
Thrombophlebitis24.01.02.0010.000213%Not Available
Tinnitus17.04.07.004; 04.04.01.002--
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 13 Pages